iPS Cells & Regenerative Medicine– category –
-
High Volume of CRISPR Therapeutics Call Options Reflects Strong Market Confidence in Gene-Editing Pipeline
MarketBeat USA Overview On June 4, 2026, CRISPR Therapeutics (NASDAQ:CRSP) experienced exceptionally high call option trading volume, indicating robust investor interest in the company. This active trading reflects sustained confidence f... -
Intellia Therapeutics to Unveil Additional Phase 3 HAELO Data for Lonvo-z, a Hereditary Angioedema Therapy, at EAACI Annual Congress
Quiver Quantitative USA Overview Intellia Therapeutics announced it would present additional Phase 3 HAELO clinical trial data for lonvo-z (lonvoguran ziclumeran), its CRISPR-based gene-editing therapy for hereditary angioedema (HAE), at... -
Fate Therapeutics’ iPSC-Derived CAR T Therapy FT836 Shows Tumor Reduction and Favorable Safety Profile in KRASwt Colorectal Cancer Phase 1 Data at ASCO
GlobeNewswire (Fate Therapeutics Press Release) USA Overview Fate Therapeutics presented preliminary Phase 1 clinical data for its iPSC-derived, off-the-shelf CAR T-cell therapy, FT836, at the 2026 American Society of Clinical Oncology (... -
Vyjuvek Secures UK MHRA Approval; REGENXBIO’s RGX-202 Achieves Primary Endpoint in Duchenne Muscular Dystrophy Phase 3 Trial
YouTube (Lucid Quest) USA Overview A May 28, 2026, update reported that Vyjuvek, a gene therapy for dystrophic epidermolysis bullosa, has received UK MHRA approval. Concurrently, REGENXBIO's RGX-202, a gene therapy for Duchenne muscular ... -
EMA Initiates Review of Otarmeni’s Hereditary Hearing Loss Gene Therapy; Eli Lilly Announces Phase 2 Plans for VERVE-102 in Cardiovascular Disease
LucidQuest Ventures USA Overview Key developments in the cell and gene therapy sector were reported on May 28, 2026, with Otarmeni's hereditary hearing loss gene therapy entering EMA review. Eli Lilly detailed its Phase 2 clinical trial ... -
CRISPR Therapeutics to Detail Broadening Gene-Editing Pipeline at June Investor Conferences, Highlighting Approved Casgevy and Multidisease Programs
Market Chameleon USA Overview CRISPR Therapeutics announced plans to present its expanding gene-editing pipeline at three major investor conferences in early June 2026. The company will discuss the commercial progress of its approved gen... -
iPS Cells & Regenerative Medicine Weekly Report May 31, 2026
📄 Weekly Report May 31, 2026 (PDF) — Download Weekly Report May 31, 2026 (PDF) — DownloadDownload 🎙 Podcast May 31, 2026 (MP3) — Play & Download iPS_RegenerativeMedicineEnglishPodcast_20260531.mp3Download -
Avaí Bio Establishes GMP-Grade Master Cell Bank for Alpha-Klotho Anti-Aging Program, Advancing Cell Therapy Toward Commercialization
PR Newswire (via USA News Group) USA Overview Avaí Bio has achieved a critical manufacturing milestone by completing its GMP-grade Master Cell Bank (MCB) for the alpha-Klotho anti-aging program. This MCB ensures a high-quality, standardi... -
Japan: AMCHEPRY® for Parkinson’s (~$350,600) and RiHEART® for Severe Heart Failure (~$63,500+) iPSC Cell Therapies Show Positive Early Clinical Results in 7 Patients
Reddit (r/stemcells) Japan Overview Early clinical trials for Japan-originated iPSC cell therapies, AMCHEPRY® for Parkinson's disease and RiHEART® for severe ischemic heart failure, have shown positive results in a total of seven patient... -
Allogene Therapeutics’ Anti-B7-H3 Allogeneic CAR γδ T Cell Therapy QH104 Shows Favorable Safety, Disease Stabilization in Leptomeningeal Metastasis Phase 1 Trial
PubMed USA Overview Allogene Therapeutics' anti-B7-H3 allogeneic CAR γδ T cell therapy, QH104, demonstrated a favorable safety profile and promising efficacy in a Phase 1 clinical trial for patients with leptomeningeal metastasis (LM) fr...
